Telaprevir: Phase III started

Vertex and Johnson & Johnson subsidiary Tibotec Pharmaceuticals Ltd. began the international Phase III ADVANCE trial in 1,050 treatment-naïve genotype 1 HCV patients to compare a 48-week regimen of P...